NYSE - Delayed Quote USD

Quest Diagnostics Incorporated (DGX)

Compare
151.79
-2.24
(-1.45%)
At close: January 10 at 4:00:02 PM EST
152.00
+0.21
+(0.14%)
After hours: January 10 at 6:16:02 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,539,000.00
9,252,000.00
9,883,000.00
10,788,000.00
9,437,000.00
Cost of Revenue
6,417,000.00
6,199,000.00
6,450,000.00
6,579,000.00
5,804,000.00
Gross Profit
3,122,000.00
3,053,000.00
3,433,000.00
4,209,000.00
3,633,000.00
Operating Expense
1,870,000.00
1,791,000.00
2,005,000.00
1,828,000.00
1,662,000.00
Operating Income
1,252,000.00
1,262,000.00
1,428,000.00
2,381,000.00
1,971,000.00
Net Non Operating Interest Income Expense
-176,000.00
-152,000.00
-138,000.00
-151,000.00
-163,000.00
Other Income Expense
37,000.00
20,000.00
-55,000.00
369,000.00
76,000.00
Pretax Income
1,113,000.00
1,130,000.00
1,235,000.00
2,599,000.00
1,884,000.00
Tax Provision
245,000.00
248,000.00
264,000.00
597,000.00
460,000.00
Earnings from Equity Interest Net of Tax
22,000.00
26,000.00
44,000.00
78,000.00
75,000.00
Net Income Common Stockholders
838,000.00
850,000.00
942,000.00
1,988,000.00
1,425,000.00
Diluted NI Available to Com Stockholders
838,000.00
850,000.00
942,000.00
1,988,000.00
1,425,000.00
Basic EPS
7.52
7.59
8.10
15.85
10.62
Diluted EPS
7.44
7.49
7.97
15.55
10.47
Basic Average Shares
111,250.00
112,000.00
116,000.00
125,000.00
134,000.00
Diluted Average Shares
111,500.00
113,000.00
118,000.00
128,000.00
136,000.00
Total Operating Income as Reported
1,252,000.00
1,262,000.00
1,428,000.00
2,381,000.00
1,971,000.00
Total Expenses
8,287,000.00
7,990,000.00
8,455,000.00
8,407,000.00
7,466,000.00
Net Income from Continuing & Discontinued Operation
841,000.00
854,000.00
946,000.00
1,995,000.00
1,431,000.00
Normalized Income
841,000.00
854,000.00
946,000.00
1,995,000.00
1,431,000.00
Interest Income
24,000.00
11,000.00
10,000.00
1,000.00
3,000.00
Interest Expense
200,000.00
163,000.00
148,000.00
152,000.00
166,000.00
Net Interest Income
-176,000.00
-152,000.00
-138,000.00
-151,000.00
-163,000.00
EBIT
1,313,000.00
1,293,000.00
1,383,000.00
2,751,000.00
2,050,000.00
EBITDA
1,780,000.00
1,732,000.00
1,820,000.00
3,159,000.00
2,411,000.00
Reconciled Cost of Revenue
6,067,000.00
5,868,000.00
6,133,000.00
6,274,000.00
5,546,000.00
Reconciled Depreciation
467,000.00
439,000.00
437,000.00
408,000.00
361,000.00
Net Income from Continuing Operation Net Minority Interest
841,000.00
854,000.00
946,000.00
1,995,000.00
1,431,000.00
Normalized EBITDA
1,780,000.00
1,732,000.00
1,820,000.00
3,159,000.00
2,411,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 12/17/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LH Labcorp Holdings Inc.
232.00
-0.99%
 
WAT Waters Corporation
380.35
+1.64%
 
QGEN Qiagen N.V.
44.68
-1.28%
 
IDXX IDEXX Laboratories, Inc.
418.05
-3.31%
 
MYGN Myriad Genetics, Inc.
14.83
+0.34%
 
CRL Charles River Laboratories International, Inc.
186.12
-0.95%
 
RVTY Revvity, Inc.
113.88
-2.18%
 
MTD Mettler-Toledo International Inc.
1,210.99
-2.85%
 
SHC Sotera Health Company
13.11
-2.09%
 
IQV IQVIA Holdings Inc.
203.27
-0.51%